XL041 (BMS-852927) is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a potent and selective antagonist of the LXR (liver X receptor) pathway, which plays a critical role in lipid metabolism and inflammation. By modulating LXR activity, it has shown promise in preclinical studies for targeting cancers that rely on lipid metabolism for growth and survival. Additionally, its anti-inflammatory properties make it a candidate for research in diseases where inflammation contributes to pathology, such as atherosclerosis or autoimmune disorders. Ongoing studies aim to explore its efficacy and safety in clinical settings for these applications.